CapsoVision, Inc. reported $14M of revenue over the trailing twelve months, +11% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $14M (to Q2 2026). Net income: −$30M, trailing twelve months to Q2 2026. Free cash flow: −$28M, trailing twelve months to Q2 2026. Operating margin: −220%, trailing twelve months to Q2 2026.

CVCapsoVision, Inc.

Healthcare

$6.62+41% 1Y

$6.62

$4.4652 weeks$14.42

Latest close: back above its 200-day averageOct 8, 2026what changed →

CV as reported

CapsoVision, Inc. reported $14M of revenue over the trailing twelve months, +11% on the year before. 9 reported series are charted on this page, each one as filed.

$14M

Revenue, trailing twelve months · to Q2 2026 · +11% against the twelve months before

Net income: −$30M
Net income · +46% year on year · trailing twelve months to Q2 2026
Free cash flow: −$28M
Free cash flow · +27% year on year · trailing twelve months to Q2 2026
Operating margin: −220%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CV, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$14M	+11%	Q2 2026
Net income	−$30M	+46%	Q2 2026
EPS	−$0.45	−95%	Q2 2026
Gross margin	51%	n/a	Q2 2026
Operating margin	−220%	n/a	Q2 2026
Net margin	−217%	n/a	Q2 2026
ROE	−165%	n/a	Q2 2026
ROA	−123%	n/a	Q2 2026
Free cash flow	−$28M	+27%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.